List of Figures:
Figure 2-1: Global - Number of Clinical Trials (2007-2009)
Figure 2-2: Global - Clinical Research Market (Billion US$), 2007-2009
Figure 2-3: Global - Forecast for Clinical Research Market (Billion US$), 2010-2012
Figure 2-4: Global - Clinical Research Market by Phase (%), 2008
Figure 2-5: Asia-Pacific - Share of Countries in Clinical Trial Studies (2008)
Figure 2-6: Number of Clinical Trials (2007-2009)
Figure 2-7: Forecast for Number of Clinical Trials (2010-2012)
Figure 2-8: Clinical Trials by Phase (%)
Figure 2-9: Clinical Trials by Therapy (%)
Figure 2-10: Clinical Research Market (Million US$), 2007-2009
Figure 2-11: Forecast for Clinical Research Market (Million US$), 2010-2012
Figure 2-12: Forecast for Number of Patients Participating in Clinical Trials (Million), 2010-2012
Figure 2-13: Pharma Outsourcing Market (Billion US$), 2007-2009
Figure 2-14: Pharma Outsourcing Market by Segment (%), 2008
Figure 3-1: Population (Million), 2006-2009
Figure 3-2: Forecast for Population (Million), 2010-2012
Figure 3-3: Population Breakup by Age Group (%), 2006-2009
Figure 3-4: Forecast for Population Breakup by Age Group (%), 2010-2012
Figure 3-5: Various Causes of Death (%), 2008
Figure 3-6: Forecast for Various Causes of Death (%), 2030
Figure 3-7: New and Total Number of Cancer Patients (‘000)
Figure 3-8: Number of Hypertension Patients (Million), 2000, 2007 & 2025
Figure 3-9: Number of Coronary Heart Patients (Million), 2005 & 2015
Figure 3-10: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
Figure 3-11: Number of Patient per Site in Comparison to US
Figure 4-1: Number of Individuals with Bachelor and Higher Degree (Million), 1991, 2004, 2006 & 2008
Figure 4-2: Number of Graduates and Postgraduates (Million), 2004
Figure 4-3: Share of Science Doctorates in Total Doctorates (2004)
Figure 4-4: Number of Doctors in Comparison to US and Germany (‘000), 2008
Figure 4-5: Number of Doctors (‘000), 2007-2009
Figure 4-6: Forecast for Number of Doctors (‘000), 2010-2012
Figure 4-7: Number of GCP Trained Investigators (2002 & 2005)
Figure 4-8: Number of GCP Trained Investigators in Comparison to US
Figure 4-9: Number of Hospital Beds (‘000), 2007-2009
Figure 4-10: Number of Hospital Beds in Comparison to UK, US and Germany (‘000), 2008
Figure 4-11: Forecast for Number of Hospital Beds (‘000), 2010-2012
Figure 4-12: Number of Sites for Clinical Trials in Comparison to UK, US and Germany
Figure 5-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-3: Average Cost per Patient for Conducting Phase II Clinical Trials in comparison to UK, US and Germany (US$)
Figure 5-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 6-1: Average Cost for Conducting Various Clinical Trial Phases in Comparison to US
Figure 6-2: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
Figure 6-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
Figure 6-4: IVD Market (Million US$), 2008 & 2012
Figure 6-5: Average Time for Approval of Clinical Trials in Comparison to UK, US and Germany (Weeks)
Figure 9-1: Share of Players in Bio-services Market (2008)
List of Tables:
Table 3-1: Number of Deaths due to Various Causes (2005)
Table 3-2: Number of Diabetic Patients in Age Group 20-79 (‘000), 2007
Table 3-3: Forecast for Number of Diabetic Patients in Age Group 20-79 (‘000), 2025
Table 3-4: New Cancers Incidences (per ‘00,000 Females), 2005
Table 3-5: New Cancers Incidences (per ‘00,000 Males), 2005
Table 3-6: Prevalence of Overweight & Obesity in Males and Females (%), 2005 & 2015
Table 4-1: Structure of Medical Education
Table 4-2: Number of GLA Approved Facilities by Type
Table 5-1: Annual Cost of Staff for Conducting Phase I Clinical Trials in comparison to UK, US and Germany (US$)
Table 5-2: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-3: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-4: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-5: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-6: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-7: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-8: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 8-1: Comparison of Factors Affecting Clinical Trials Market among Different Countries
